cystic fibrosis transmembrane conductance regulator inhibitor (Discovery BioMed)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namecystic fibrosis transmembrane conductance regulator inhibitor (Discovery BioMed)
Drug Alias NameCFTR inhibitor (Discovery BioMed)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsDiarrheaPolycystic Kidney, Autosomal Dominant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDiscovery BioMed Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDiscovery BioMed Inc
Active IndicationsN/A
Inactive IndicationsDiarrheaPolycystic Kidney, Autosomal Dominant

Other Information

ATC CodeN/A
Related LinksN/A